FK506 ameliorates oxidative damage and protects rat brain following transient focal cerebral ischemia

Neurological Research

Volumn 33, Issue 8, 2011, Pages 881-889

  Nito, Chikako ^a   Ueda, Masayuki ^a   Inaba, Toshiki ^a   Katsura, Ken ichiro ^a   Katayama, Yasuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

FK506; Focal ischemia; Inflammation; Neuroprotection; Oxidative stress

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; PROTEIN; PROTEIN IBA 1; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PROTECTION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; OXIDATIVE STRESS; RAT; SINGLE DRUG DOSE;

ALDEHYDES; ANIMALS; ANTIOXIDANTS; BRAIN; CALCIUM-BINDING PROTEINS; CEREBRAL INFARCTION; CEREBROVASCULAR CIRCULATION; DEOXYGUANOSINE; DISEASE MODELS, ANIMAL; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; ISCHEMIC ATTACK, TRANSIENT; MAGNETIC RESONANCE IMAGING; MALE; MICROFILAMENT PROTEINS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80855150827     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132811Y.0000000019     Document Type: Article

References (26)

1. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, et al. The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial. Stroke 2008;39:3268-76.
2. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432-8.
3. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994;344:423-8.
4. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK506 for liver, kidney, and pancreas transplantation. Lancet 1989;2:1000-4.
5. Liu J, Farmer JD, Jr, Lane WS, Friedman J, Weissman I, Schreiber SL. Calcineurin is a common target of cyclophilincyclosporin A and FKBP-FK506 complexes. Cell 1991;66:807-15.
6. Tocci MJ, Matkovich DA, Collier KA, Kwok P, Dumont F, Lin S, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989;143:718-26.
7. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci USA 1993;90:9808-12.
8. Sharkey J, Butcher SP. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 1994;371:336-9.
9. Furuichi Y, Katsuta K, Maeda M. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and longterm efficacy. Brain Res 2003;965:137-45.
10. Aoyama S, Katayama Y, Terashi A. The effect of FK506, an immunosuppresant, on cerebral infarction volume in focal cerebral ischemia in rats. Nippon Ika Daigaku Zasshi 1997;64:416-21.
11. Arii T, Kamiya T, Arii K, Ueda M, Nito C, Katsura KI, et al. Neuroprotective effect of immunosuppressant FK506 in transient focal ischemia in rat: Therapeutic time window for FK506 in transient focal ischemia. Neurol Res 2001;23:755-60.
12. Floyd RA, Carney JM. Free radical damage to protein and DNA: mechanisms involved and relevant observations on brain undergoing oxidative stress. Ann Neurol 1992;32:S22-7.
13. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609-23.
14. Barone FC, Arvin B, White RF, Miller A, Webb CL, Willette RN, et al. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 1997;28:1233-44.
15. Boutin H, LeFeuvre RA, Horai R, Asano M, Iwakura Y, Rothwell NJ, et al. Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 2001;21:5528-34.
16. Williams DS, Detre JA, Leigh JS, Koretsky AP. Magnetic resonance imaging of perfusion using spin inversion of arterial water. Proc Natl Acad Sci USA 1992;89:212-6.
17. Ewing JR, Wei L, Knight RA, Pawa S, Nagaraja TN, Brusca T, et al. Direct comparison of local cerebral blood flow rates measured by MRI arterial spin-tagging and quantitative autoradiography in a rat model of experimental cerebral ischemia. J Cerebral Blood Flow Metab 2003;23:198-209.
18. Yonemori F, Yamaguchi T, Yamada H. Evaluation of a motor deficit after chronic focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1998;18:1099-106.
19. Kinouchi H, Epstein CJ, Mizui T, Carlson E, Chen SF, Chan PH. Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc Natl Acad Sci USA 1991;88:11158-62.
20. Kitagawa K, Matsumoto M, Oda T, Niinobe M, Hata R, Handa N. Free radical generation during brief period of cerebral ischemia may trigger delayed neuronal death. Neuroscience 1990;35:551-8.
21. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128.
22. Toyokuni S, Uchida K, Okamoto K, Hattori-Nakakuki Y, Hiai H, Stadtman ER. Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc Natl Acad Sci USA 1994;91:2616-20.
23. Yoshino H, Hattori N, Urabe T, Uchida K, Tanaka M, Mizuno Y. Postischemic accumulation of lipid peroxidation products in the rat brain: immunohistochemical detection of 4-hydroxy-2-nonenal modified proteins. Brain Res 1997;767:81-6.
24. Nagayama T, Lan J, Henshall DC, Chen D, O'Horo C, Simon RP, et al. Introduction of oxidative DNA damage in the peri-infarct region after permanent focal cerebral ischemia. J Neurochem 2000;75:1716-28.
25. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PK. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 1992;149:2736-41.
26. Zawadzka M, Kaminska B. A novel mechanism of FK506-mediated neuroprotection: downregulation of cytokine expression in glial cells. Glia 2004;49:36-51.